Terms: = Bone cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Diagnosis
3 results:
1. Evaluation of expression profiles of microRNAs and two target genes, foxo3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer.
Jurkovicova D; Magyerkova M; Sestakova Z; Copakova L; Bella V; Konecny M; Krivjanska M; Kulcsar L; Chovanec M
Neoplasma; 2016; 63(6):941-951. PubMed ID: 27596294
[TBL] [Abstract] [Full Text] [Related]
2. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract] [Full Text] [Related]
3. Covert preleukemia driven by MLL gene fusion.
Zuna J; Burjanivova T; Mejstrikova E; Zemanova Z; Muzikova K; Meyer C; Horsley SW; Kearney L; Colman S; Ptoszkova H; Marschalek R; Hrusak O; Stary J; Greaves M; Trka J
Genes Chromosomes Cancer; 2009 Jan; 48(1):98-107. PubMed ID: 18932267
[TBL] [Abstract] [Full Text] [Related]
